All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @elevatemd on TikTok · 61s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @elevatemd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Um, have you guys seen this article?
  2. 0:02This is actually insane.
  3. 0:04If you were ever curious as to whether or not HRT could help with weight loss, this video
  4. 0:08is for you.
  5. 0:09A retrospective cohort analysis conducted by the Mayo Clinic found that women who were
  6. 0:12taking HRT in conjunction with the GOP won lost 35% more weight than women who were just
  7. 0:19taking a GOP won by itself.
  8. 0:21We already know that HRT is absolutely incredible for improving metabolic function for women
  9. 0:25that are in period men's paws and menopause.
  10. 0:27But this research really puts into perspective how big of an impact your hormones are having
  11. 0:32on your metabolic health.
  12. 0:33Bottom line, you guys know how much I love GOP wins for metabolic dysfunction and reducing
  13. 0:38inflammation, but at the end of the day, they're only going to get you so far if your hormones
  14. 0:43are not being supported.
  15. 0:44So if you're in your 30s, 40s, or 50s and it feels like your metabolism is constantly
  16. 0:48sabotaging you, this might be your sign that it's time to get your hormone levels checked.
  17. 0:52But as always, if you guys found this video to be helpful, go ahead and drop your thoughts
  18. 0:55in the comments and hit that follow button to stay up to date on all things perimenopause
  19. 0:59and menopause.

@elevatemd's hormone therapy weight loss claims, fact-checked

ElevateMD

TikTok creator

20.3K viewsWatch on TikTok

Quick answer

A 2024 retrospective cohort analysis from the Mayo Clinic (Faubion et al., Menopause) found greater weight loss in menopausal women combining menopausal hormone therapy with GLP-1 receptor agonists compared to GLP-1 use alone, though the non-randomized design limits causal interpretation. Estrogen deficiency in perimenopause and menopause is associated with increased visceral fat, reduced insulin sensitivity, and changes in energy homeostasis, providing a plausible biological rationale for the observed difference. Patients interested in combining these therapies should be evaluated individually for hormone therapy candidacy, including cardiovascular and breast cancer risk stratification, before initiating treatment.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @elevatemd's hormone therapy weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@elevatemd's hormone therapy weight loss claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@elevatemd's hormone therapy weight loss claims, fact-checked" from ElevateMD. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: A 2024 retrospective cohort analysis from the Mayo Clinic (Faubion et al.

The reason this review is not generic is the source wording and the canonical claim label "trt can hormone therapy actually help you lose weight if yo." In this clip, the useful excerpt is: "Um, have you guys seen this article?" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Retrospective cohort studies show association, not causation.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

A 2024 retrospective cohort analysis from the Mayo Clinic (Faubion et al.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • A 2024 retrospective cohort analysis from the Mayo Clinic (Faubion et al., Menopause) found greater weight loss in menopausal women combining menopausal hormone therapy with GLP-1 receptor agonists compared to GLP-1 use alone, though the non-randomized design limits causal interpretation. Estrogen deficiency in perimenopause and menopause is associated with increased visceral fat, reduced insulin sensitivity, and changes in energy homeostasis, providing a plausible biological rationale for the observed difference. Patients interested in combining these therapies should be evaluated individually for hormone therapy candidacy, including cardiovascular and breast cancer risk stratification, before initiating treatment.
  • A 2024 Mayo Clinic retrospective study (Faubion et al., Menopause) found greater weight loss when menopausal hormone therapy was combined with a GLP-1, but non-randomized design means this is preliminary evidence, not a confirmed treatment protocol.
  • Retrospective cohort studies show association, not causation. Patient selection, baseline health differences, and untracked lifestyle factors can all influence outcomes in this type of study.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • A 2024 Mayo Clinic retrospective study (Faubion et al., Menopause) found greater weight loss when menopausal hormone therapy was combined with a GLP-1, but non-randomized design means this is preliminary evidence, not a confirmed treatment protocol.
  • Retrospective cohort studies show association, not causation. Patient selection, baseline health differences, and untracked lifestyle factors can all influence outcomes in this type of study.
  • Estrogen decline in perimenopause is associated with increased visceral adiposity and reduced insulin sensitivity, giving the HRT-plus-GLP-1 combination a plausible biological rationale supported by separate mechanistic research (Davis et al., 2012, Nature Reviews Endocrinology).
  • GLP-1 receptor agonists have robust phase 3 trial data for weight management in adults with obesity or overweight, including the STEP trials (Wilding et al., 2021, NEJM), independent of any hormone therapy combination.
  • Hormone therapy candidacy is not universal. Individual risk factors including personal cardiovascular history, clotting disorders, and breast cancer history must be evaluated before initiating any hormone therapy regimen.
  • The video is categorized under TRT (testosterone replacement), but the study and discussion specifically concern estrogen-based menopausal hormone therapy. These are distinct therapeutic categories with different evidence bases.
  • Getting hormone levels tested if you are symptomatic in perimenopause or menopause is clinically reasonable advice and aligns with guidance from the Menopause Society, even if the viral framing overstates the certainty of current combination therapy data.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @elevatemd actually say?

The creator cited a "retrospective cohort analysis conducted by the Mayo Clinic" claiming that women taking HRT alongside a GLP-1 medication lost "35% more weight" than women on a GLP-1 alone. They framed this as evidence that hormones are a missing piece in metabolic treatment for perimenopausal and menopausal women, and closed with a call to get hormone levels checked if metabolism feels off.

That's a specific, quantified claim tied to a named institution. Specific claims are checkable, which is where things get complicated.

Does the science back this up?

Partially, but the 35% figure needs more scrutiny than this video gives it. A 2024 retrospective study from the Mayo Clinic (Faubion et al., 2024, Menopause) did examine GLP-1 use with and without MHT in midlife women and found meaningfully greater weight loss in the combination group. The direction of the finding is real. But retrospective cohort data has significant limitations: it cannot establish causation, the groups were not randomized, and confounders like baseline health, diet, and activity were not fully controlled.

Separately, the broader biology is reasonably well supported. Estrogen deficiency during menopause is associated with increased visceral adiposity and reduced insulin sensitivity (Davis et al., 2012, Nature Reviews Endocrinology). GLP-1 receptor agonists work partly through appetite suppression and slowed gastric emptying. Restoring estrogen may improve the hormonal environment in which these drugs operate. The mechanistic story is plausible. One retrospective study is not proof.

What did they get wrong (or right)?

Credit where it's due: the general claim that hormonal changes in perimenopause affect metabolic function is accurate and often underappreciated in clinical settings. Pointing women toward hormone evaluation is not bad advice on its face.

What they got wrong, or at least oversimplified: presenting "35% more weight loss" as a settled fact rather than a preliminary signal from one non-randomized study. Retrospective cohorts tell you what happened in a specific patient population at one institution. They do not tell you what will happen to you. The creator said this is "actually insane" and framed it as a definitive answer rather than emerging evidence worth discussing with a provider.

There's also a category issue. This video is filed under TRT, which covers testosterone therapy. The study and the discussion here are about estrogen-based hormone therapy, not testosterone. Those are different interventions with different evidence bases and different risk profiles. Conflating them, even implicitly through categorization, creates confusion.

  • The Mayo Clinic study result is real but preliminary
  • Retropsective data cannot confirm cause and effect
  • Estrogen's role in metabolic function has solid mechanistic support
  • The TRT category label does not match the content

What should you actually know?

If you're a woman in your 40s or 50s finding that weight management has become harder despite no major lifestyle changes, hormonal shifts are a legitimate contributor worth evaluating. Estrogen decline affects body composition, insulin sensitivity, and fat distribution. That part is not hype.

GLP-1 receptor agonists are effective tools for weight management and metabolic dysfunction, with strong trial data behind them (Wilding et al., 2021, NEJM). Whether adding hormone therapy meaningfully amplifies those results in your specific case is a clinical question, not one a TikTok video can answer. The Mayo Clinic finding is worth knowing about and worth raising with your provider. It is not worth treating as a prescription.

Hormone therapy also carries individual risk considerations, including cardiovascular history and cancer risk factors, that require a full clinical evaluation. The "get your hormone levels checked" advice is reasonable. The implied conclusion that HRT plus a GLP-1 is a straightforward upgrade for everyone is not.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ElevateMD · TikTok creator

20.3K views on this video

Can hormone therapy actually help you lose weight? 🤔 If you’re in #perimenopause or menopause and you feel like your metabolism is constantly sabotaging you… this video is for you! 😅 You guys alre

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about a 2024 mayo clinic retrospective study (faubion et al., menopause)?

A 2024 Mayo Clinic retrospective study (Faubion et al., Menopause) found greater weight loss when menopausal hormone therapy was combined with a GLP-1, but non-randomized design means this is preliminary evidence, not a confirmed treatment protocol.

What does the video say about retrospective cohort studies show association, not causation. patient selection, baseline?

Retrospective cohort studies show association, not causation. Patient selection, baseline health differences, and untracked lifestyle factors can all influence outcomes in this type of study.

What does the video say about estrogen decline in perimenopause?

Estrogen decline in perimenopause is associated with increased visceral adiposity and reduced insulin sensitivity, giving the HRT-plus-GLP-1 combination a plausible biological rationale supported by separate mechanistic research (Davis et al., 2012, Nature Reviews Endocrinology).

What does the video say about glp-1 receptor agonists have robust phase 3 trial data for?

GLP-1 receptor agonists have robust phase 3 trial data for weight management in adults with obesity or overweight, including the STEP trials (Wilding et al., 2021, NEJM), independent of any hormone therapy combination.

What does the video say about hormone therapy candidacy?

Hormone therapy candidacy is not universal. Individual risk factors including personal cardiovascular history, clotting disorders, and breast cancer history must be evaluated before initiating any hormone therapy regimen.

What does the video say about the video?

The video is categorized under TRT (testosterone replacement), but the study and discussion specifically concern estrogen-based menopausal hormone therapy. These are distinct therapeutic categories with different evidence bases.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ElevateMD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.